CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to VNDA

Tasimelteon Oral Capsule, Tasimelteon Liquid Suspension

Phase 3
Vanda Pharmaceuticals Inc. (VNDA)

Phase 3

Development Phase

0

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

1 competitor in Autism Spectrum Disorder

View Full Landscape
Drug Information

Target Indication

Autism Spectrum Disorder

Clinical Trial

NCT05361707

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.